Empower Your Business Success! Streamline with innovative user centric solutions

We build and support scalable user centric innovative Software and Remote Managed Service Solutions for healthcare and evolving businesses.

Bring AI Into Your Workflow With Confidence

Optimize operations. Reduce costs. Unlock data-powered intelligence.

Learn More

Value of ‘User Centric’, innovative, scalable and smart Workflow Software Solutions

At Aryabh Consulting Inc, we specialize in delivering cost-effective, high-quality innovative business workflow solutions tailored to meet the unique needs of healthcare and businesses of any scale. Our solutions are designed to enhance efficiency, minimize overhead costs, evolve with changing needs and drive sustainable growth— not just serve as temporary fixes.

Key Business Benefits partnering with Aryabh Consulting Inc

Cost-Effective, High-Quality
                                                Innovative Scalable Solutions

Cost-Effective, High-Quality Innovative Scalable Solutions

Our pricing is highly competitive compared to other premium business solutions in the industry.

We provide a robust alternative to off-the-shelf software, ensuring higher ROI without unnecessary expenses.

Evolve to Your Business Needs

Evolve to Your Business Needs

Every business is unique and has its own nuances. Our solution will be designed with your input to match your specific operational workflows.

We work closely with our clients to design software that adapts to their evolving needs.

Increased Efficiency & Reduced
                                                Overheads

Increased Efficiency & Reduced Overheads

Automate repetitive processes to reduce manual work and errors.

Streamline operations to save time and cut operational costs.

Enduring Partnership Beyond Launch

Enduring Partnership Beyond Launch

We assign dedicated resources to ensure seamless post-launch assistance.

No concerns about system downtime or lack of technical support.

Full Knowledge Transfer &
                                                Documentation

Full Knowledge Transfer & Documentation

We provide complete access to our code-base with proper documentation

Detail User Guide with Video tutorials

If needed, businesses can transition software maintenance to a third party without dependency on us.

Long-Term Partnership, Not Just
                                                Software Delivery

Long-Term Partnership, Not Just Software Delivery

We do not believe in delivering "just another software"—our goal is to provide lasting solutions that scale with your business.

We take on projects only when we can dedicate focused resources to support the software through its lifecycle.

At Aryabh Consulting Inc, we prioritize customer success, efficiency, and sustainability in every project. Our commitment is to empower businesses with solutions that evolve with them, ensuring long-term value.

What We Offer

Unlock new possibilities and achieve lasting growth with our innovative solutions.

Empower Your Workflow, Elevate Your Success

Empower Your Workflow Elevate
                        Your Success

Why us

We’re not just building an IT company but committed to leaving a legacy of innovation, creativity, possibilities and transparency. We aim to be an extension of your business, fostering trusted partnerships that drive success together.

Read more

Our Vision

To be a trusted partner in digital tranformation — driven by sincere partnerships, unwavering commitment, and transparent collaboration — empowering organizations to build a sustainable and digitally forward future.

Our Mission

We deliver transformative digital products and services with integrity and purpose. Through close partnerships, open communication, and a deep commitment to excellence, we enable our clients to grow with confidence in an ever-evolving digital world.

TECH INSIGHTS

Healthcare IT & Digital Transformation
HIPAA Risk Assessments in 2026. What OCR Is Actually Auditing For

For years, a HIPAA risk assessment was treated like a form to file away. Do it once, keep the PDF, and move on. That approach is now a liability. OCR's third phase of HIPAA compliance audits is already underway, and enforcement patterns from 2024 through 2026 show a clear shift. Risk analysis remains the single most cited deficiency in OCR investigations, and the bar for what counts as "accurate and thorough" has gone up. If your organization handles ePHI in any form, from an EHR to a claims management system to a connected medical device, this is the year to take a hard look at how your risk assessment actually holds up. Key 2026 Compliance Shifts The proposed 2026 Security Rule update has not been finalized. OCR is still enforcing the current security rule, but the direction is obvious even without a final rule in place. Three things have changed in practice. Scope is now explicit. A risk analysis that only covers your primary EHR no longer satisfies the rule. It needs to account for cloud systems, mobile devices, contractor laptops, connected medical device software, and every third-party integration that touches ePHI. Methodology has to be documented, not just the output. OCR wants to see how you identified threats, how you scored likelihood and impact, and why a given risk was rated medium instead of high. A risk register with no explanation behind it reads as guesswork. Asset inventory is now treated as a prerequisite. You cannot analyze risk to systems you have not listed. OCR expects a current inventory of everything that creates, stores, or transmits ePHI before it will accept the analysis built on top of it. Alongside this, the modernization of 42 CFR Part 2 is pulling substance use disorder confidentiality rules closer to HIPAA, which means consent workflows, EHR tagging, and business associate agreements need another look if your organization touches SUD data. What OCR Is Targeting in 2026 Audits Enforcement data from recent settlements points to a fairly consistent list of pressure points. Risk analysis and risk management sit at the top. OCR is not just asking whether you did an assessment. It wants proof you acted on what the assessment found, with owners and timelines attached to each remediation item. Ransomware readiness and breach response are getting close attention, including how fast notifications go out and whether the content meets the rule's requirements. Business associate oversight is another recurring theme. Vendors with access to ePHI, including software vendors and IT service providers, are expected to be vetted and monitored, not just signed to a BAA and forgotten. Rights of access enforcement continues, particularly around how quickly patients get their records and how parental access to minors' records is handled. Tracking technologies on patient-facing websites and portals are also under review, since improper use of analytics and marketing pixels has triggered breach notifications in past cases. Core Expectations for an Audit-Ready SRA An audit-ready security risk assessment in 2026 needs a few things that a bare-minimum version usually skips. A current, complete asset inventory covering on-premise systems, cloud infrastructure, remote endpoints, and any medical device software connected to your network. A written methodology explaining how risks are identified and scored so the reasoning behind every rating can be defended if OCR asks. A risk management plan with assigned owners, deadlines, and a review cadence, not just a list of findings sitting in a spreadsheet. Executive sign-off, since OCR increasingly expects leadership to be accountable for risk acceptance decisions, not just IT staff. Evidence of an annual update cycle, plus documented triggers for off-cycle reviews after a new system, merger, or security incident. Essential Steps to Complete Your Assessment Start by building or refreshing the ePHI asset inventory. Every system, application, and device that touches patient data needs to be on the list, including anything run by a vendor. Identify threats and vulnerabilities against that inventory, covering technical gaps like unpatched software and firmware, along with process gaps like weak access controls or missing encryption. Score likelihood and impact using a documented method, and write down the reasoning, not just the final number. Build a risk management plan that assigns each finding to a specific owner with a real deadline. Get sign-off from leadership on the analysis and the plan, and keep that documentation on file. Set a recurring schedule for updates, at minimum annually, with clear triggers for revisiting the analysis sooner. What Organizations Must Do Now Waiting for the final security rule before acting is a mistake. Every proposed requirement in the draft rule already reflects current security best practice, so there is little reason to delay. Organizations that put this off until a final rule lands will be working against an implementation timeline that may not be realistic. Practically, this means auditing your current SRA against the 2026 expectations above, closing the gap on asset inventory and methodology documentation, and making sure your vendor and business associate relationships are actually being monitored rather than just documented once at onboarding. How Will This Affect Organizations Small practices feel this differently than large health systems, but nobody is exempt. A small practice using a generic EHR and a handful of vendors still needs a documented inventory and methodology, even if the process is simpler. Larger systems with multiple facilities, integrated claims management systems, and connected medical devices face a heavier lift, since their attack surface and vendor list are both larger. Software vendors and healthcare IT solutions providers are affected too. If your product touches ePHI, your customers' auditors will eventually ask about your security posture, which puts pressure on vendors to build compliance in from the start rather than bolting it on later. Where ACI Fits In This is where Aryabh Consulting Inc. comes in. ACI works with healthcare organizations on healthcare software development that treats HIPAA compliance as part of the build, not an afterthought. That includes EHR and EMR integrated solutions, HIPAA-compliant claims management system builds, and healthcare IT solutions designed around how a practice actually documents care and processes claims, rather than a generic off-the-shelf template. For organizations working with connected medical device software or agentic automation, ACI builds with role-based access, encryption, and audit logging from the ground up, so the systems feeding your risk assessment are defensible rather than a liability sitting inside it. As one of the Healthcare Software Development Companies in USA that works directly with practices on their coding, claims, and EMR workflows, ACI can help you look at where your current systems create audit exposure and what a properly integrated build would fix. Frequently Asked Questions What is an OCR audit? An OCR audit is a review conducted by HHS's Office for Civil Rights to check whether a covered entity or business associate is meeting HIPAA requirements. It typically examines risk analysis, risk management, breach notification practices, and safeguards around ePHI. What are the HIPAA updates for 2026? The main update is a proposed security rule revision that adds more specific, prescriptive requirements around risk analysis, asset inventory, encryption, and multi-factor authentication. It has not been finalized, but OCR's current enforcement already reflects this direction. The Part 2 rule aligning substance use disorder confidentiality with HIPAA is also being phased in through 2026. What is OCR in relation to HIPAA? OCR, the Office for Civil Rights within HHS, is the federal agency responsible for enforcing HIPAA. It investigates complaints, conducts audits, and issues civil monetary penalties for violations. What is the main goal of OCR audits? The main goal is to confirm that covered entities and business associates are actually protecting patient data, not just documenting that they intend to. OCR wants to see risk analysis translated into real, tracked remediation, not paperwork sitting in a drawer. Closing Thought A HIPAA risk assessment in 2026 is not a document you file once a year and forget. It is a living record of what you found, what you fixed, and who owns what comes next. If your current assessment cannot answer those questions clearly, now is the time to fix that, before OCR asks first. We'd love to hear from you Contact Us

  • 17 September, 2026
  • 8 min Read
Read More
HIPAA Risk Assessments in 2026. What OCR Is Actually Auditing For
Software as a Medical Device (SaMD)
Software as a Medical Device (SaMD). What FDA Classification Means for Your Build Timeline

If you are building healthcare software that touches diagnosis, treatment, or patient monitoring, one decision shapes your entire roadmap before a single line of code matters. That decision is FDA classification. Most founders and product teams treat FDA classification as a legal formality they will "figure out later." That is a costly mistake. The classification your product falls under determines your testing requirements, your documentation load, your clinical evidence needs, and often your launch date by six months to two years. Get it wrong early and you rebuild later. Get it right early and you build once. At ACI, we have guided healthcare software teams through this exact process for years. We know the regulations because we live inside them, and we know the software because we build it. This gives us a rare vantage point most development shops do not have. Below we break down what FDA classification actually means, the risks of underestimating it, and the factors that will make or break your timeline. What Is Software as a Medical Device Software as a Medical Device, or SaMD, is software intended for one or more medical purposes that performs these purposes without being part of a hardware medical device. Think diagnostic apps, AI powered imaging tools, clinical decision support software, and remote patient monitoring platforms. Not every piece of healthcare software qualifies as SaMD. A scheduling app for a clinic is not regulated the same way as software that interprets an EKG. The line between "health adjacent" and "medical device" is where a lot of teams get tripped up, and it is exactly where FDA classification enters the picture. Why FDA Classification Comes First FDA classification places your product into Class I, Class II, or Class III based on the risk it poses to the patient. Class I covers low risk devices with general controls. Think basic tracking or wellness tools. Class II covers moderate risk devices that usually require a 510(k) submission, showing your product is substantially equivalent to an already cleared device. Class III covers high risk devices, often requiring Premarket Approval, the most rigorous and lengthy pathway the FDA offers. Your classification is not a checkbox you tick after development. It is the foundation your entire build plan sits on. The class determines what evidence you need, what testing you must run, what documentation you must produce, and how the FDA will review your submission. Skip this step or guess at it, and you are building on sand. The Real Risks of Getting FDA Classification Wrong Teams that treat FDA classification as an afterthought tend to run into the same problems. Redesign after the fact. If your software was built assuming Class I requirements but the FDA determines it belongs in Class II, you may need to add features like audit trails, risk documentation, or clinical validation that were never part of your original architecture. That is not a small patch. That is often a rebuild. Missed submission windows. The FDA does not work on your schedule. A submission returned with additional information requests can push your launch back by months. Teams that did not plan documentation alongside development end up scrambling to produce evidence that should have existed from day one. Funding and investor risk. Investors and partners want to see a realistic regulatory pathway, not a vague promise that "we'll handle FDA stuff later." Misjudging your classification early can shake confidence and stall a raise. Recalls and post market consequences. The FDA does not only enforce rules before launch. Look at how seriously the agency treats consumer product safety even outside medical devices. The FDA deodorant recall in recent years is a good reminder that the agency moves fast and publicly when safety concerns surface, regardless of product category. Medical software carries even higher stakes, because errors can directly affect patient outcomes. A rushed or poorly classified product that reaches market can face corrective action, forced updates, or in serious cases, a full recall. None of these risks are hypothetical. They happen regularly to teams that treat regulatory strategy as separate from healthcare software development instead of part of the same process. Key Factors That Impact Your Build Timeline Once your FDA classification is clear, several factors decide how long your build will actually take. Intended use statement. How you define what your software does and who it is for directly shapes your regulatory pathway. A vague or overly broad intended use invites more scrutiny and a longer review. Level of clinical evidence required. Class II and Class III devices often need clinical validation data. Planning this early, rather than bolting it on after the software is "done," saves months. Quality management system. The FDA expects a documented quality system covering design controls, risk management, and change tracking. Building this alongside your software, not after, keeps your timeline realistic. Cybersecurity and data requirements. Medical Device Software must meet strict standards for data integrity and cybersecurity under FDA guidance. Retrofitting security architecture late in development is one of the most common causes of delay. Interoperability with existing health systems. If your software needs to integrate with EHR platforms or hospital systems, that adds testing cycles and validation steps that should be mapped from the start. Team experience with FDA pathways. Development teams that have never worked through an FDA submission tend to underestimate documentation and testing time by a wide margin. Working with a partner who has been through this before removes a lot of guesswork. Why ACI We built our process around one idea. Regulatory strategy and software development should never be separate tracks that collide at the end. At ACI, our teams plan FDA classification requirements into your architecture from the first sprint, not after a beta version is already built. We have worked across Class I, Class II, and Class III products, and we understand where teams typically lose time, money, and momentum. Healthcare software development is not just about writing clean code. It is about writing code that can survive an FDA review, hold up under audit, and protect patients once it is live. That is the standard we build to. Final Thought FDA classification is not paperwork you handle after the product works. It is the framework that decides how the product gets built in the first place. Teams that plan around it early move faster, spend less, and launch with fewer surprises. If you are early in planning a SaMD product and want a clear read on where your software likely falls and what that means for your timeline, our team at ACI is glad to talk it through with you. We'd love to hear from you Contact Us

  • 08 September, 2026
  • 7 min Read
Read More
Software as a Medical Device (SaMD). What FDA Classification Means for Your Build Timeline